Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

ABSTRACT:

Introduction

CLR1404 is a theranostic molecular agent that can be radiolabeled with ¹²⁴I (CLR 124) for positron emission tomography (PET) imaging, or ¹³¹I (CLR 131) for single-photon emission computed tomography (SPECT) imaging and targeted radionuclide therapy. This pilot study evaluated a pretreatment dosimetry methodology in a triple-negative breast cancer patient who was uniquely enrolled in both a CLR 124 PET imaging clinical trial and a CLR 131 therapeutic dose escalation clinical trial.

Materials and methods

Three-dimensional PET/CT images were acquired at 1, 3, 24, 48, and 120 h postinjection of 178 MBq CLR 124. One month later, pretherapy 2D whole-body planar images were acquired at 0.25, 5, 24, 48, and 144 h postinjection of 370 MBq CLR 131. F

SUBMITTER: Besemer AE 

PROVIDER: S-EPMC6383576 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature